ArticleInternational journal of general medicine2026
Prognostic Value of Systemic Inflammatory Indices in Hospitalized Patients with HFrEF: A Multicenter Retrospective Cohort Study.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study sought to examine the associations between four inflammatory biomarkers and 1-year adverse cardiovascular outcomes among hospitalized patients with heart failure with reduced ejection fraction (HFrEF) and to compare their prognostic performance. Methods: A multicenter retrospective cohort study was conducted involving 1814 hospitalized patients with HFrEF (LVEF <40%). Four inflammation-derived biomarkers were derived from standard blood test results. The relationships between these biomarkers and the 1-year incidence of adverse cardiovascular outcomes were analyzed using Cox proportional hazards regression and restricted cubic spline (RCS) modeling. Event-free survival across biomarker tertiles was compared via Kaplan-Meier survival analysis. The discriminative ability of each biomarker was assessed through receiver operating characteristic (ROC) curves, time-dependent ROC analyses, and C-statistics. Additional sensitivity analyses were performed to verify the stability and reliability of the results. Results: Elevated levels of all four biomarkers were significantly associated with an increased risk of adverse cardiovascular outcomes in patients with HFrEF. Each 1-SD increase in systemic inflammation response index (SIRI), systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and monocyte-to-lymphocyte ratio (MLR) was associated with a 32.5%, 46.1%, 54.0%, and 98.3% higher hazard of adverse cardiovascular outcomes, respectively. Tertile analyses showed that the increased risk of adverse cardiovascular outcomes was mainly observed in the highest biomarker tertiles. Among the four markers, SIRI showed better discriminative performance than the other indices in this cohort, with an AUC of 0.705, which was supported by time-dependent ROC and C-statistic analyses. Conclusion: Higher SIRI, SII, NLR, and MLR levels were associated with an increased risk of adverse cardiovascular outcomes in patients with HFrEF. SIRI showed numerically better discrimination among hospitalized patients with HFrEF in this cohort, but further external validation is required before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.